Core Viewpoint - Weigao Blood Purification plans to acquire 100% equity of Shandong Weigao Puri Pharmaceutical Packaging for approximately 8.511 billion yuan, expanding its business into pharmaceutical packaging materials [1] Group 1: Company Overview - Weigao Blood Purification primarily focuses on the research, development, production, and sales of medical products in the blood purification field [1] - The acquisition will add the research, development, production, and sales of pre-filled drug delivery systems and automatic safety drug delivery systems to the company's main business [1] Group 2: Strategic Implications - Post-acquisition, the company aims to integrate the target company's technological expertise and product layout to expand its product line into the pharmaceutical packaging sector [1] - The collaboration is expected to leverage the company's hollow fiber filtration technology advantages alongside the target company's extensive customer resources in the biopharmaceutical sector, facilitating mutual empowerment in biopharmaceutical filter business [1]
威高血净拟收购威高普瑞100%股权，作价85.11亿元